BioCryst's Orladeyo Oral Pellets Win FDA Nod For HAE Patients 2 To Under 12

The FDA approved BioCryst’s Orladeyo (berotralstat) oral pellets for prophylactic treatment of hereditary angioedema (HAE) in children aged 2 to under 12, a child‑friendly formulation supported by interim APeX‑P data showing the drug was well tolerated, maintained a consistent safety profile, and delivered early, sustained reductions in monthly attack rates (most common adverse event: nasopharyngitis). This pediatric approval expands the drug’s addressable market on top of the December 2020 clearance for patients 12 and older, complements ongoing filings with the EMA and Japan’s PMDA, and comes as Orladeyo generated $159.1 million in Q3 2025 revenue (up 37% YoY) and BioCryst raised full‑year 2025 guidance to $590–$600 million, with U.S. sales accounting for roughly 89% of quarterly revenue—indicating material near‑term upside to sales growth subject to international regulatory outcomes.

Analysis

BioCryst announced FDA approval of Orladeyo (berotralstat) oral pellets for prophylactic treatment of hereditary angioedema (HAE) in pediatric patients aged 2 to under 12 years, providing a child‑friendly administration option. HAE often presents in childhood with about 40% of patients experiencing their first attack by age 5, which underscores the clinical relevance of this new formulation for a debilitating, potentially life‑threatening disorder.

The approval was supported by interim APeX‑P data — described as the largest long‑term pediatric prophylaxis study — showing Orladeyo was well tolerated, maintained a consistent safety profile, and produced early, sustained reductions in monthly attack rates; the most common treatment‑emergent adverse event was nasopharyngitis. These data reduce near‑term clinical risk for pediatric commercialization but require continued readouts for broader stakeholder confidence.

On the commercial front, Orladeyo generated $159.1 million in Q3 2025 revenue (up 37% year‑over‑year) and BioCryst raised full‑year 2025 guidance for Orladeyo to $590–$600 million, indicating the product is a material revenue driver. U.S. sales accounted for roughly 89% of the quarter's revenue, and regulatory filings for the pellet are under review at the EMA and Japan's PMDA with additional filings planned, making international approvals the primary growth lever.

The stock has traded between $6.00 and $11.31 over the past year and closed at $7.58 yesterday (down 1.04%), with sentiment modestly positive (per‑ticker sentiment 0.7) but a limited near‑term market‑impact score. Key risks include the timing and outcomes of international regulatory reviews, pediatric uptake and reimbursement dynamics, and longer‑term APeX‑P data that could influence adoption.

Key Decisions for Investors

• Consider modestly increasing exposure to BCRX to reflect the expanded pediatric indication and raised full‑year guidance, while keeping position sizes prudent given execution risk
• Monitor EMA and PMDA decisions and any commercialization updates in Europe and Japan closely, as international approvals are the primary catalyst to reduce the company's 89% U.S. revenue concentration
• Follow APeX‑P ongoing data releases and safety updates for pediatric efficacy and tolerability signals, since changes could materially affect adoption and reimbursement
• Manage downside risk with position sizing or hedges given the stock's $6.00–$11.31 12‑month trading range and the modest near‑term market impact; re‑assess after clear international approvals or visible pediatric uptake metrics